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Abstract: Background. Chronic diarrhea after kidney
transplantation is often attributed to mycophenolic acid (MPA)
toxicity. We hypothesize that intestinal infections contribute to the
pathogenesis of chronic MPA-associated diarrhea.
Methods. In this retrospective study, all patients (n = 726) receiving
a kidney transplant between 2000 and 2010 at the University Hospital
Zurich were followed until July 2014 for occurrence of chronic
diarrhea (≥4 weeks). Infectious triggers at diarrhea onset were
assessed by reviewing medical history, stool microbiology, and
histology of colon biopsies.
Results. In 46 patients (6.3% of the cohort), a total of 51 episodes of
chronic diarrhea during MPA treatment were documented. The
diarrhea episodes were often severe, as confirmed by significant
weight loss. The cumulative incidence of chronic diarrhea was
uniformly distributed throughout the post-transplant period, with
2.0%, 5.1%, and 9.6% at 1, 5, and 10 years, respectively. Evidence was
found for intestinal infection at diarrhea onset in 38 episodes (74.5%).
Occurrence of diarrhea onset showed a seasonal distribution with
peaks in April and October/November. Specific antimicrobial
treatment alone was associated with a 19% resolution rate only,
whereas combination with dose reduction of MPA or switch from
mycophenolate mofetil to enteric-coated mycophenolate sodium
resulted in a 22.7% and 76.5% resolution rate, respectively. Change to
an MPA-free regimen was associated with a 100% resolution rate.
Conclusion. These results provide first evidence for a contribution of
intestinal infections in chronic post-transplant diarrhea associated
with MPA treatment.
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Chronic diarrhea after kidney transplantation is com-
mon, yet often neglected despite substantially affect-
ing quality of life (1) and graft and patient survival
(2–5). The cause of chronic diarrhea in transplant
recipients has typically been attributed to drug
toxicity (5), especially related to mycophenolic acid
(MPA) (6). However, growing evidence indicates that
infections are involved as causative factors of chronic
diarrhea in immunosuppressed patients, with a par-
ticular role for gastrointestinal (GI) viral infections
(7–11). The balance, resulting from the interaction
between pathogens, intestinal flora, immune system,
and pharmacological therapy, merits further investi-
gation.
MPA was introduced into clinical transplantation in
1995 (12) and has become a first-line immunosuppres-
sive drug. It is part of the standard therapy in solid
organ transplantation and is overall well tolerated.
Two therapeutically equivalent preparations (13, 14)
are currently on the market: (i) mycophenolate mofetil
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(MMF, Cellcept), a prodrug that needs to be
converted into MPA, and (ii) the enteric-coated
mycophenolate sodium (EC-MPS, Myfortic) (15),
developed to reduce GI side effects (16). In both
cases, MPA is the active drug, which acts as a non-
competitive inhibitor of inosine-50 monophosphate
dehydrogenase, the rate-limiting enzyme in de novo
purine synthesis. As a result, MPA suppresses DNA
synthesis and cell proliferation with a relative selec-
tivity for B and T cells, as lymphocytes are completely
inosine-50 monophosphate-dehydrogenase-dependent
for de novo purine synthesis. In contrast, enterocytes,
even though rapidly dividing, are less susceptible to
the effects of MPA, as the salvage pathway for purine
synthesis is active in these cells. Nevertheless, colon
biopsies from patients treated with MPA and suffering
from chronic diarrhea show prominent anti-prolifera-
tive effects on the GI mucosa (6, 17). Histologically, 2
different morphologic patterns can be distinguished:
(i) predominant crypt distortion, also called inflamma-
tory bowel disease-like MPA-associated toxicity, and
(ii) predominant apoptosis, also called graft-versus-
host-like MPA-associated toxicity (6). Because chronic
diarrhea generally is recognized as a common side
effect of treatment with MPA, clinical practice consists
of dose reduction or switch of immunosuppression.
Dose reduction, however, is not without risk, as a
reduced dose of MMF has been associated with
increased risk for acute graft rejection (relative risk
increase by 4% for every week that the MMF dose was
reduced below the full dose) (18). Whether switch of
immunosuppression from MMF to EC-MPS helps
reducing diarrhea symptoms is a matter of debate.
Diverse open-labeled studies reported reduced lower
GI side effects with EC-MPS compared with MMF (16,
19), but this benefit was not confirmed in randomized,
blinded trials showing an incidence of diarrhea at
1 year of 5% for both drug formulations (13, 14). In
most centers, a switch from MPA to azathioprine
(AZA) (3 Imurek) is usually avoided because of
reported reduced graft survival with AZA as compared
to MMF (12), although this approach is safe in the
short-term (20).
The exact mechanism of MPA-associated colitis
remains unknown. Direct cytotoxicity leading to inflam-
mation and suppressed intestinal regeneration, as well as
dysregulation of the balance between immunity and
tolerance against luminal antigens, have been proposed
(6, 15, 17). Here, we show that an infectious agent is
detected in the majority of patients at onset of diarrhea,
suggesting that intestinal infections might be involved in
the pathophysiology of MPA-associated chronic diar-
rhea.
Methods
Study design and population
We performed a single-center retrospective, observa-
tional cohort study. We screened all adult renal
allograft recipients transplanted at the University
Hospital Zurich (Switzerland) between January 2000
and December 2010 for occurrence of chronic diarrhea
until July 2014. All patients were seen at least annually
in the transplant center and at regular intervals by the
local nephrologists. In case of graft dysfunction or
other clinically relevant problems, patients were
referred to the transplant center more frequently.
Immunosuppression therapy was administered accord-
ing to our internal guidelines. Induction therapy with
basiliximab or anti-thymocyte globulin was included in
patients at high risk for rejection. Maintenance
immunosuppression consisted mostly of a calcineurin
inhibitor (cyclosporine or tacrolimus) and an anti-
proliferative drug (usually MPA). In most cases,
steroids were withdrawn 6 months after transplanta-
tion. Cytomegalovirus (CMV) prophylaxis or preemp-
tive monitoring was performed according to the
individual patient risk profile (21).
To screen for chronic diarrhea, the standardized
electronic patient files were reviewed for episodes of
diarrhea since transplantation. Adult patients
(>18 years of age) during immunosuppression with
MPA at diarrhea onset and suffering from chronic
diarrhea, defined as diarrhea lasting for at least
1 month according to the Centers for Disease Control
and Prevention classification (22), were included.
Patients with combined solid organ transplantation
were excluded from the study. Patients with pre-
existing GI diseases (e.g., inflammatory bowel disease)
or chronic diarrhea before transplantation were also
excluded. The study was performed with the approval
of the local ethics committee (protocol number: KEK-
ZH-Nr. 2014-0522).
Data collection
Demographic data including age, gender, cause of end-
stage renal disease, and death, if applicable, were
collected. With respect to transplantation, the date,
initial immunosuppressive regimen, and CMV status
were recorded. For characterization of chronic diar-
rhea, the onset and resolution dates and the accompa-
nying change in body weight were documented.
Evidence for an infectious trigger was defined as the
2 Transplant Infectious Disease 2016: 0: 1–9
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presence of one or more of the following parameters at
diarrhea onset: travel history; environmental history for
diarrhea; microbiological evidence of a pathogen in a
stool sample/culture positivity for Shigella, Salmonella,
or Campylobacter; positivity for Clostridium difficile
toxin; detection of norovirus by polymerase chain
reaction (PCR) testing (introduced in 2004); detection
of parasites; or detectable CMV in peripheral blood
(viral load >200 copies/mL or pp65 antigen positivity at
time of diarrhea onset) or in an intestinal biopsy. If
available, intestinal histology was included. Type, dose,
and change of the immunosuppressive regimen during
chronic diarrhea were monitored (particularly regard-
ing anti-proliferative agents such as MMF, EC-MPF, or
AZA).
Statistics
Descriptive statistics of the variables analyzed are
presented as mean,  standard deviation, or  standard
error of the mean. For comparison of independent
samples, Student’s t-test was used. Comparison of
related samples was done with the paired t-test. Event-
free (i.e., diarrhea-free) survival was analyzed using the
Kaplan–Meier method. For comparison of seasonal
variation, an analysis of variance calculation (Kruskal–
Wallis test) was performed. The effect of different
treatments on diarrhea resolution, as compared to no
intervention, was compared using Fisher’s exact test. All
analyses were done using Graph Pad Prism Software.
Results
Study population
From 2000 to 2010, a total of 726 patients received a
kidney transplant (451 from deceased and 275 from
living donors) and had at least 1 follow-up visit at the
University Hospital of Zurich until July 2014. Median
follow-up was 8.25 years (3012 days; interquartile
range [IQR] 1787–3858 days). Median age at trans-
plantation was 54 years (IQR 42–59 years). Among all
kidney transplant recipients, 65 patients (9%) developed
at least 1 episode of chronic diarrhea during the period
of observation. Of those, 19 patients were excluded
because of having chronic diarrhea already before
transplantation (n = 3), known inflammatory bowel
disease (n = 4), MPA-free immunosuppression at diar-
rhea onset (n = 2), incomplete records (n = 8), exo-
crine pancreas insufficiency (n = 1), or microscopic
colitis (n = 1). Thus, 46 patients (6.3% of the cohort)
with a total of 51 episodes of chronic diarrhea were
included for further analysis (Fig. 1). The immunosup-
pressive treatment at diarrhea onset included MMF in
45 episodes and EC-MPS in 6 episodes.
Table 1 summarizes the baseline characteristics of
these patients. As compared with the whole transplant
cohort, no statistical differences were seen in terms of
gender (P = 0.77), age (P = 0.79), or donor type
(P = 0.09) between the group of transplant recipients
with chronic diarrhea versus those without.
MPA-associated diarrhea is a clinically relevant
problem
The clinical course of chronic diarrhea during MPA
therapy was typically characterized by acute onset of
watery diarrhea, followed by incomplete remission
leading to persistent or frequently relapsing bouts of
diarrhea. The median duration of chronic diarrhea was
247 days (IQR 64–446 days). The mean overall weight
loss from onset to resolution of diarrhea was 5.5 kg (95%
confidence interval [CI]7.6 to3.5 kg,P < 0.001), i.e.,
7.3% (95% CI 10.1 to 4.5%) of body weight. Some
patients lost >15 kg of their body weight (Figure S1).
MPA-associated chronic diarrhea is not increased
during the first post-transplant year but shows
seasonal peaks
To investigate our hypothesis of an infectious trigger of
MPA-associated chronic diarrhea, as opposed to a drug
Excluded:       
19 patients
Included:            
46 patients with 
51 episodes
Chronic diarrhea:                  
65 patients
Mean Follow up: 6.5 years
Screened:                  
726 patients
Fig. 1. Patient flowchart.
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toxicity effect alone, we first assessed the time-point of
diarrhea onset after transplantation. The onset of
chronic diarrhea was uniformly distributed throughout
the follow-up period (Fig. 2). Of note, the incidence of
chronic diarrhea was not particularly high within the
first months post transplantation and initiation of MPA
treatment. Cumulative incidence of chronic diarrhea
was 2.0%, 5.1%, and 9.6% at 1, 5, and 10 years,
respectively. Furthermore, we observed 2 seasonal
peaks, with higher incidence of diarrhea onset in April
and in October–November, in contrast to a very low
incidence in summer (Fig. 3A and B) (P = 0.038).
Thus, we did not observe an early peak of chronic
diarrhea onset after transplantation, but a seasonal
variation.
Intestinal infections are frequently present at the
onset of MPA-associated diarrhea
In a second analysis, we systematically assessed the
clinical reports focusing on direct and indirect
evidence for infectious triggers at diarrhea onset
(Fig. 4). Direct evidence of infectious diarrhea was
defined by positive microbiological analysis. We found
evidence for bacterial enteritis in 4 episodes (2
Campylobacter jejuni, 1 Salmonella enteritis, 1
Mycobacterium tuberculosis). In addition, C. difficile
toxin was detected in 2 episodes and parasites in 7
episodes (Hymenolepis, Microsporidia, Isospora belli,
and/or Dientamoeba). In 15 episodes, norovirus was
found in stool specimens; in 7 episodes, CMV was
detected in blood at diarrhea onset; and in 6
episodes, CMV colitis was found by immunohisto-
chemistry of intestinal biopsies. Indirect evidence for
an infectious diarrhea was defined by highly
Baseline characteristics
Variable N = 46
Age year: median (interquartile range) 54 (42–59)
Male gender, n (%) 29 (63.0)
Cause of end-stage renal disease, n (%)
Glomerulonephritis 11 (23.9)
Diabetes mellitus 1 (2.2)
Arterial hypertension 3 (6.5)
Pyelonephritis or interstitial nephritis 4 (8.7)
Polycystic kidney disease 10 (21.7)
Uncertain 7 (15.2)
Other 10 (21.7)
Diabetes mellitus, n (%) 6 (13.0)
Donor type, n (%)
Living 11 (23.9)
Deceased 35 (76.1)
Transplantation, n (%)
First kidney 37 (80.4)
Second/third kidney 7 (15.2)
Kidney + islets 1 (2.2)
ABO incompatible 1 (2.2)
CMV status, n (%)
High risk (D+/R) 11 (25)
Intermediate risk (R+) 25 (56.8)
Low risk (D/R) 8 (18.1)
Initial post-operative immunosuppression, n (%)
CsA + MMF + PDN 20 (43.5)
CsA + MMF + PDN + Basiliximab 5 (10.9)
CsA + MMF + PDN + ATG 2 (4.3)
CsA + EC-MPS + PDN 2 (4.3)
CsA + EC-MPS + PDN + Basiliximab 1 (2.2)
Tac + MMF + PDN 14 (30.4)
Tac + MMF + PDN + Basiliximab 2 (4.3)
CMV, cytomegalovirus; D, donor; R, recipient; CsA, cyclosporine;
MMF, mycophenolate mofetil; PDN, prednisone; ATG, anti-thymo-
cyte globulin; EC-MPS, enteric-coated mycophenolate sodium; TAC,
tacrolimus.
Table 1
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Fig. 2. Incidence of chronic diarrhea after kidney transplantation.
Kaplan–Meier estimation of “chronic diarrhea-free” survival for
kidney transplant patients during immunosuppressive treatment with
mycophenolic acid (MPA).
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suggestive reports in the medical history and was
present in 11 episodes. In 8 episodes of diarrhea, a
recent relevant travel history was reported, and in 6
episodes, similar symptoms were reported in other
family members (with some overlap between the 2
criteria). Collectively, and in consideration of overlap-
ping clinical and microbiological results (i.e., some
patients had direct and indirect evidence for infec-
tious diarrhea), evidence for an infectious trigger at
diarrhea onset was identified in 38 episodes of
chronic diarrhea (74.5%). In 34 episodes, this was
supported by microbiological analyses, and in 4
episodes, the evidence for infection was only indirect.
Colonoscopy was performed in 31 episodes (60.8%).
Intestinal biopsies revealed typical histopathological
features of MPA-associated diarrhea in 13 (42%)
episodes with increased number of apoptotic cells and
typical intestinal crypt distortion; 10 episodes (32.3%)
had evidence of predominant inflammation; and in 8
(25.8%), no histopathological changes were described.
MPA sustains rather than induces chronic diarrhea
Several changes in therapy were attempted to control
chronic diarrhea. In general, if possible, antimicrobial
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Fig. 3. Seasonal distribution of onset of
chronic diarrhea episodes. (A) Diarrhea
onset depicted for each month. (B)
Seasonal clustering of diarrhea onset.
Number of diarrhea episodes per season
as compared with Kruskal–Wallis test.
Boxes depicting maximum, minimum, and
mean number of episodes during the
observed 3-month seasonal period.
History Microbiology
4 277 13
History
Travel 8 (15.7%)
Environment 6 (11.8%)
Microbiology
Bacterial 4 (7.8%)
C. difficile (toxin) 2 (3.9%)
Norovirus 15 (29.4%)
CMV (viremia) 6 (11.8%)
CMV (biopsy) 7 (13.7%)
Parasites 7 (13.7%) 
Fig. 4. Evidence for infectious triggers at diarrhea onset. All patients with chronic diarrhea are depicted in the rectangular box. The left circle
includes patients with indirect evidence for an infection at diarrhea onset (travel history, environmental history). The right circle includes patients
with direct microbiological evidence for an infection at diarrhea onset. The overlap shows the patients with both direct and indirect evidence.
Multiple infectious triggers were detected for several episodes of chronic diarrhea, as indicated. C., Clostridium; CMV, cytomegalovirus.
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therapy was given first. In case of persistence,
changes in immunosuppression such as dose reduc-
tion and switch from MMF to EC-MPS or to an MPA-
free regimen were attempted to control chronic
diarrhea by the treating physicians (Fig. 5A). As a
result, chronic diarrhea fully resolved in 45 of 51
episodes (88.2%); in 6 cases (11.8%), diarrhea per-
sisted. In 2 episodes (6.7%), the chronic diarrhea
resolved without any intervention. In patients treated
with antimicrobial therapy alone, resolution of diar-
rhea was observed in 19% of episodes. MPA dose
reduction was associated with resolution of diarrhea
in 22.7% of episodes. Switch from MMF to EC-MPS
was followed by resolution of diarrhea in 76.5% of
cases (P < 0.001) and switch to an MPA-free regimen
was followed by resolution of diarrhea in 100% of
episodes (P < 0.001). Of note, switch to an MPA-free
regimen with AZA was significantly more efficient
than continuation of MPA (P = 0.032) (Fig. 5B and
C), and was associated with significantly faster
resolution of diarrhea: median time to resolution
after switch to AZA: 19 days (IQR 6–35 days) versus
63 days (IQR 11–69 days) after switch from MMF to
EC-MPS, P = 0.0009 (Figure S2). Interestingly, in 5
cases, MPA (MMF in 1 episode and EC-MPS in 4
episodes) was re-introduced following diarrhea
resolution. None of these patients presented a diar-
rhea relapse after re-exposure to MPA (median
follow-up 117 days, IQR 21–743 days), supporting
the hypothesis that MPA toxicity alone is not
sufficient to explain chronic diarrhea in transplant
patients.
Discussion
Chronic diarrhea is a major problem after transplan-
tation. It substantially reduces quality of life, leads to
malabsorption with significant weight loss and oxalate
nephropathy (9, 10), and is associated with reduced
graft and patient survival (2–5). Although the majority
of published studies on post-transplant diarrhea con-
sider acute and chronic diarrhea in general, in this
study we focused on chronic diarrhea, defined as
diarrhea lasting for >1 month (22). We found a
cumulative incidence of chronic diarrhea of 2.0%,
5.1%, and 9.6% at 1, 5, and 10 years after kidney
transplantation. This lower incidence, compared with
previous reports (5), is likely related to our strict
definition of chronic diarrhea aiming at investigating
patients with a clinically relevant condition. Therapy
for chronic diarrhea in kidney transplant recipients is
Antimicrobial
Therapy
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Dose reduction
Switch 
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MPA to AZA
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Treatment category Resolution per category in %
(cases resolved / cases treated)
No Change 6.7 (2/30)
Antimicrobial Therapy 19 (4/21)
Dose reduction of IS 22.7 (5/22)
Switch of IS from MMF to EC-MPS 76.5 (13/17)
Switch of IS from MPA to AZA 100 (21/21)
Fig. 5. Treatment strategies and related outcomes in episodes of chronic diarrhea during mycophenolic acid (MPA) treatment. (A) General
stepwise approach for treating episodes of chronic diarrhea during MPA treatment. (B) Changes in treatment regimen and diarrhea resolution
rate per category. (C) Comparison of therapeutic efficacy of the different treatment categories by Fisher’s exact test. MMF, mycophenolate
mofetil; EC-MPS, enteric-coated mycophenolate sodium; AZA, azathioprine; IS, immunosuppression.
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challenging, as etiology often remains unclear (5). In
the absence of a specific cause, diarrhea has usually
been attributed to MPA toxicity, even though the
exact mechanism is unknown (17). This retrospective,
observational study in 726 patients with a total of 51
episodes of chronic diarrhea identifies a high inci-
dence of intestinal infections at onset of chronic post-
transplant diarrhea and suggests that infections might
play an important role in the pathophysiology of
chronic post-transplant diarrhea, which is typically
attributed to MPA toxicity.
The following findings support the hypothesis of a
critical role of an infectious trigger in chronic post-
transplant diarrhea:
1 The uniform annual incidence of chronic diarrhea
onset after transplantation, with some patients devel-
oping diarrhea several years after first exposure to
MPA. This suggests that an additional trigger is
required for initiating diarrhea. If drug toxicity would
be sufficient for induction of chronic diarrhea, a peak
incidence in the first months after drug initiation
would be expected.
2 The seasonal distribution of diarrhea onset with
highest incidence in April and October/November
and lowest in July. Coste et al. (8) report a similar
seasonal clustering with highest rates of enteric
pathogens in stool samples of kidney transplant
patients in March and October.
3 Detection of an intestinal infection at the onset of 75%
of all episodes of chronic diarrhea, despite the
retrospective study design and limited sensitivity of
conventional methods to find enteric pathogens.
Indeed, a recent study showed that conventional
methods detected enteric pathogens in 23% of stool
samples only, whereas novel multiplex PCR assays
were able to identify enteric pathogens in 72% of stool
samples (8). We observed a high incidence of viral
pathogens, predominantly of norovirus and CMV
infections. This finding is in line with a recent report
showing that norovirus and sapovirus infections
account for half of the cases of previously classified
“diarrhea with unknown causes” and for 30% of the
whole cohort of patients suffering from chronic
diarrhea (10). Notably, some of the bacteria and
parasites identified in the stool at diarrhea onset are
not necessarily pathogenic, or classical causes of
chronic diarrhea. We speculate that, in the multifac-
torial complex pathogenesis of chronic diarrhea after
transplantation, these microorganisms might indeed
damage the intestinal mucosa and trigger intestinal
inflammation, but this hypothesis needs to be
validated in other studies.
4 The observation that switching back from AZA to
MPA was not associated with re-occurrence of
diarrhea suggests that drug toxicity is not sufficient
for chronic post-transplant diarrhea.
These findings are compatible with a 2-hit mecha-
nism on the intestinal mucosa leading to chronic post-
transplant diarrhea, i.e., infection-induced damage
combined with reduced repair capacity. MPA impairs
pathogen clearance and mucosal repair through its
immunosuppressive effects on lymphocytes, the asso-
ciated hypogammaglobulinemia (23), and inhibition of
purine synthesis. Hence, it substantially inhibits epithe-
lial regeneration, especially in the intestine, owing to
high local activity because of enterohepatic recircula-
tion. Histological evidence of apoptosis and crypt
distortion, known features of MPA-associated colitis
(24), was found in 42% of our cases. The crucial role
of the integrity of the epithelial lining for resolution of
diarrheal symptoms is supported by the description
of recovery from diarrhea with reduction of immuno-
suppression, despite persistence of norovirus shedding,
and its reoccurrence after augmentation of the dose (7,
10). This effect of the epithelial lining explains why
specific anti-infectious treatment alone may not be
sufficient to stop diarrhea, if regeneration of entero-
cytes is strongly impaired. However, re-introduction of
MPA after regeneration of the epithelial lining is safe, if
an additional infectious trigger has been eliminated,
either by antimicrobial treatment or by restoration of
the immunological defense in case of viral infections. In
treatment-refractory cases, a transient conversion to an
MPA-free regimen with AZA may allow for epithelial
recovery and hence resolve chronic refractory post-
transplant diarrhea, as evidenced by a 100% resolution
rate observed in our cohort. Similar resolution rates
have previously been reported after a switch to AZA
(10).
The consistent medical records documentation and
the long follow-up time strengthen our finding of an
additional “infectious” trigger as key element for
induction of chronic MPA-associated diarrhea. How-
ever, this study has several limitations. Conclusions
regarding resolution of MPA-associated diarrhea fol-
lowing changes in immunosuppressive drug regimen
are limited by the retrospective design of our study and
heterogeneity of treatment changes in patients suffer-
ing from chronic diarrhea. As such, Figure 5A shows
only the overall stepwise approach of treatment adjust-
ments. Furthermore, we did not routinely monitor MPA
drug levels as they are known to show large intra- and
inter-individual pharmacokinetic variability (15). There-
fore, no correlation could be made between MMF dose
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and risk of chronic diarrhea. Similarly, effects of
additional immunosuppressive drugs, such as cal-
cineurin inhibitor levels that might increase with
diarrhea-associated dehydration and therefore limit
clearance of infections, have not been investigated.
Hence, owing to lack of drug level monitoring and lack
of biopsy results in half of the patients, we cannot
exclude that chronic diarrhea in some of our patients
was just a result of over-immunosuppression and
related reduction of immune defense and not associ-
ated with pathognomonic MMF-associated injury of
epithelial lining. As such, immunosuppressed patients
are generally more likely to suffer from chronic
infections (also chronic intestinal infections, i.e.,
norovirus-related diarrhea). Finally, clearance of infec-
tion was not systematically monitored during follow-up.
To conclude, despite the limitations of a retrospective
observational study, our data shed light on the
causative factors of chronic post-transplant diarrhea
and support a new hypothesis for the pathophysiology
of this clinically relevant condition. We provide evi-
dence for an infectious agent at diarrhea onset playing
an important role, in combination with MPA-based
immunosuppression and associated impaired epithelial
regeneration, in the development of chronic post-
transplant diarrhea. Hence, therapeutically, this implies
that both clearance of infection and change or dose
reduction in immunosuppression are necessary to
resolve chronic post-transplant diarrhea. If confirmed
in prospective studies, this hypothesis needs to be
validated in interventional studies.
Acknowledgement:
Disclosure: The authors declare no conflicts of interest.
Funding: No funding was received for this study.
References
1. Ekberg H, Kyllonen L, Madsen S, Grave G, Solbu D, Holdaas H.
Clinicians underestimate gastrointestinal symptoms and
overestimate quality of life in renal transplant recipients: a
multinational survey of nephrologists. Transplantation 2007; 84
(8): 1052–1054.
2. Altiparmak MR, Trablus S, Pamuk ON, et al. Diarrhoea following
renal transplantation. Clin Transplant 2002; 16 (3): 212–216.
3. Zhao YJ, Wen JQ, Cheng K, et al. Late, severe, noninfectious
diarrhea after renal transplantation: high-risk factors, therapy,
and prognosis. Transplant Proc 2013; 45 (6): 2226–2232.
4. Gil-Vernet S, Amado A, Ortega F, et al. Gastrointestinal
complications in renal transplant recipients: MITOS study.
Transplant Proc 2007; 39 (7): 2190–2193.
5. Bunnapradist S, Neri L, Wong W, et al. Incidence and risk factors
for diarrhea following kidney transplantation and association with
graft loss and mortality. Am J Kidney Dis 2008; 51 (3): 478–486.
6. Liapis G, Boletis J, Skalioti C, et al. Histological spectrum of
mycophenolate mofetil-related colitis: association with apoptosis.
Histopathology 2013; 63 (5): 649–658.
7. Schorn R, Hohne M, Meerbach A, et al. Chronic norovirus
infection after kidney transplantation: molecular evidence for
immune-driven viral evolution. Clin Infect Dis 2010; 51 (3):
307–314.
8. Coste JF, Vuiblet V, Moustapha B, et al. Microbiological
diagnosis of severe diarrhea in kidney transplant recipients by
use of multiplex PCR assays. J Clin Microbiol 2013; 51 (6):
1841–1849.
9. Aulagnon F, Scemla A, DeWolf S, Legendre C, Zuber J. Diarrhea
after kidney transplantation: a new look at a frequent symptom.
Transplantation 2014; 98 (8): 806–816.
10. Roos-Weil D, Ambert-Balay K, Lanternier F, et al. Impact of
norovirus/sapovirus-related diarrhea in renal transplant
recipients hospitalized for diarrhea. Transplantation 2011; 92 (1):
61–69.
11. Cippa PE, Schiesser M, Ekberg H, et al. Risk stratification for
rejection and infection after kidney transplantation. Clin J Am Soc
Nephrol 2015; 10 (12): 2213–2220.
12. van Gelder T, Hesselink DA. Mycophenolate revisited. Transpl
Int 2015; 28 (5): 508–515.
13. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated
mycophenolate sodium is therapeutically equivalent to
mycophenolate mofetil in de novo renal transplant patients. Am J
Transplant 2004; 4 (2): 231–236.
14. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate
sodium can be safely administered in maintenance renal
transplant patients: results of a 1-year study. Am J Transplant
2004; 4 (2): 237–243.
15. Staatz CE, Tett SE. Pharmacology and toxicology of
mycophenolate in organ transplant recipients: an update. Arch
Toxicol 2014; 88 (7): 1351–1389.
16. Reinke P, Budde K, Hugo C, et al. Reduction of gastrointestinal
complications in renal graft recipients after conversion from
mycophenolate mofetil to enteric-coated mycophenolate sodium.
Transplant Proc 2011; 43 (5): 1641–1646.
17. Al-Absi AI, Cooke CR, Wall BM, Sylvestre P, Ismail MK, Mya M.
Patterns of injury in mycophenolate mofetil-related colitis.
Transplant Proc 2010; 42 (9): 3591–3593.
18. Knoll GA, MacDonald I, Khan A, Van Walraven C.
Mycophenolate mofetil dose reduction and the risk of acute
rejection after renal transplantation. J Am Soc Nephrol 2003; 14
(9): 2381–2386.
19. Sabbatini M, Capone D, Gallo R, et al. EC-MPS permits lower
gastrointestinal symptom burden despite higher MPA exposure
in patients with severe MMF-related gastrointestinal side-effects.
Fundam Clin Pharmacol 2009; 23 (5): 617–624.
20. Wuthrich RP, Cicvara S, Ambuhl PM, Binswanger U. Randomized
trial of conversion from mycophenolate mofetil to azathioprine
6 months after renal allograft transplantation. Nephrol Dial
Transplant 2000; 15 (8): 1228–1231.
21. Fehr T, Cippa PE, Mueller NJ. Cytomegalovirus post kidney
transplantation: prophylaxis versus pre-emptive therapy? Transpl
Int 2015; 28 (12): 1351–1356.
22. CDC. Chronic diarrhea. Centers for Disease Control and
Prevention, ????. Available at: http://www.cdc.gov/
healthywater/hygiene/disease/chronic_diarrhea.html (Accessed
?????). 4
8 Transplant Infectious Disease 2016: 0: 1–9
von Moos et al: Intestinal infection and MPA-related diarrhea
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
23. Keven K, Sahin M, Kutlay S, et al. Immunoglobulin deficiency in
kidney allograft recipients: comparative effects of mycophenolate
mofetil and azathioprine. Transpl Infect Dis 2003; 5 (4): 181–186.
24. Heller T, van Gelder T, Budde K, et al. Plasma concentrations of
mycophenolic acid acyl glucuronide are not associated with
diarrhea in renal transplant recipients. Am J Transplant 2007; 7
(7): 1822–1831.
Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Figure S1. Weight course during episodes of chronic
diarrhea. Comparison of weight at onset of diarrhea
and at resolution of chronic diarrhea by paired Stu-
dent’s t-test.
Figure S2. Time to diarrhea resolution. Time to
diarrhea resolution after switching immunosuppression
to azathioprine (AZA) as compared to switch from
MMF to EC-MPS. Comparison using log-rank test.
MMF, mycophenolate mofetil; EC-MPS, enteric-coated
mycophenolate sodium.
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